Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003959 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome
A Phase 1 study of Leukemia and Myelodysplastic Syndromes, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT00003959: Completed Phase 1 study of Leukemia and Myelodysplastic Syndromes, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003959 is a Phase 1 study of Leukemia and Myelodysplastic Syndromes that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 1 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003959, a Phase 1 study of Leukemia and Myelodysplastic Syndromes, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: A vaccine made from a person's myelodysplasia cells may make the body build an immune response to kill cancer cells. Combining vaccine therapy with sargramostim may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating patients who have myelodysplastic syndrome.
Conditions Studied
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL ras peptide cancer vaccine
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 1999-06 |
| Phase | Phase 1 |
What the finished NCT00003959 record still lists
NCT00003959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 2 interventions - of which sargramostim is the first listed.
NCT00003959 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00003959 about?
NCT00003959 is a clinical study titled "Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome". RATIONALE: A vaccine made from a person's myelodysplasia cells may make the body build an immune response to kill cancer cells. Combining vaccine therapy with sargramostim may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus sargramostim in treating ...
What is the current status of trial NCT00003959?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 1999-06.
What conditions does trial NCT00003959 study?
This clinical trial studies the following conditions: Leukemia, Myelodysplastic Syndromes.
What interventions are being tested in trial NCT00003959?
The interventions under investigation include: sargramostim (BIOLOGICAL), ras peptide cancer vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003959?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003959 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003959's enrollment target sits among peer trials
1 233rd of 233 the lowest of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Revumenib in Combination With 7+3 + Midostaurin in AML
RECRUITING · Phase 1
-
CIML NK Cells With Venetoclax for AML
RECRUITING · Phase 1
-
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
RECRUITING · Phase 1
-
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 1
-
A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia
RECRUITING · Phase 1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia